



*Resolution No. 04-2023-92*

# WHITE MOUNTAIN APACHE TRIBE

A Sovereign Tribal Nation

**(Authorizing Whiteriver Service Unit to publish manuscript titled “Outcome comparison of American Indian children under the age of 2-years who did or did not receive prophylactic palivizumab for respiratory syncytial virus”)**

---

**WHEREAS**, Pursuant to Article IV, Section 1(a) of the Constitution of the White Mountain Apache Tribe (“Tribe”), *inter alia*, the Tribal Council has the authority “[t]o represent the Tribe and act in all matters that concern the welfare of the Tribe”; and

**WHEREAS**, The Tribe, in conjunction with the Whiteriver Service Unit, has worked to raise the level of health of all residents of the Reservation; and

**WHEREAS**, American Indians, particularly rural populations, including members of the Tribe, are disparately impacted by respiratory syncytial virus (RSV), a leading cause of hospitalization among young children; and

**WHEREAS**, Palivizumab is an FDA-approved medication used to prevent severe RSV infections in children; and

**WHEREAS**, The White Mountain Apache Tribe has been specifically identified by the American Academy of Pediatrics as an entity that may consider increased eligibility of palivizumab prophylaxis in young children based on circumstances; and

**WHEREAS**, In the face of relatively unique seasonality of RSV in recent years that may have increased the number of children in the Tribe susceptible to RSV infection, the Whiteriver Service Unit greatly expanded eligibility for palivizumab to all children under 2 years; and

**WHEREAS**, Upon review of all RSV infections among service population, the Whiteriver Service Unit observed a remarkable reduction in RSV infections and RSV hospitalizations among children who received palivizumab; and

**WHEREAS**, The Council finds that support of the Whiteriver Service Unit’s manuscript is in the best interests of the Tribe and its members, and agrees that the manuscript will support expanded access of important therapies to the Tribe and other American Indian communities.

**BE IT RESOLVED** by the Tribal Council of the White Mountain Apache Tribe that it hereby authorizes the Whiteriver Service Unit to publish the proposed manuscript titled, “Outcome comparison

***Resolution No. 04-2023-92***



of American Indian children under the age of 2-years who did or did not receive prophylactic palivizumab for respiratory syncytial virus”, as described herein.

**BE IT FURTHER RESOLVED** by the Tribal Council of the White Mountain Apache Tribe that it hereby directs that in the event this Resolution directly conflicts with the Tribal Constitution, Tribal Ordinances, or any material facts concerning the issues presented are later found to be false, this Resolution shall be deemed null and void and have no legal effect.

**BE IT FURTHER RESOLVED** by the Tribal Council of the White Mountain Apache Tribe that it hereby directs that in the event that this Resolution conflicts with a prior Resolution or Policy, this Resolution shall supersede and govern over the conflicting subject matter.

**BE IT FURTHER RESOLVED** by the Tribal Council of the White Mountain Apache Tribe that the Chairman, or in his absence, the Vice-Chairman, is hereby authorized to execute any and all documents necessary to effectuate the intent of this Resolution.

The foregoing resolution was on APRIL 12, 2023 duly adopted by a vote of NINE for, ONE against, and ZERO abstentions by the Tribal Council of the White Mountain Apache Tribe, pursuant to authority vested in it under the enumerated powers listed in Article IV, Section 1 of the WMAT Constitution, so ratified on November 10, 2021, and federally recognized pursuant to Section 16 of the Indian Reorganization Act of June 18, 1934 (48 Stat. 984).

	<u>4.14.23</u>		<u>4/14/2023</u>
Kasey Velasquez, Chairman	Date	Vaneysa Johnson, Tribal Secretary	Date